Peter WT Pisters, M.D., president of UT MD Anderson, said the honorees represent the institution’s commitment to excellence in research, patient care, prevention and education. Their work reflects the increasingly integrated nature of modern oncology, in which progress depends not only on developing new drugs, but also on understanding tumor biology, identifying patients most likely to benefit from particular interventions, improving radiation delivery, expanding access to prevention programs and designing safer systems of care. Together, these efforts support MD Anderson’s mission to end cancer and extend the reach of advances to patients and communities worldwide.

The Jack and Beverly Randall Prize for Excellence in Cancer Care, which carries a $100,000 award, was presented this year to Hilary Ma, M.D., a professor in General Oncology. Established in 2011 by Jack and Beverly Randall, the prize recognizes vision and creativity in cancer research and clinical care, alternating annually between researchers and clinicians. The award reflects the growing importance of care models that combine scientific innovation with practical clinical judgment. In oncology, breakthroughs become meaningful only when they can be delivered safely, equitably and efficiently to people facing complex diseases, often alongside surgery, radiation, systemic therapy and supportive care.

Jeffrey Gershenwald, M.D., professor of Surgical Oncology, and Mark Bedford, Ph.D., professor of Epigenetics and Molecular Carcinogenesis, received the R. Lee Clark Prize. The award, established in 2016 through the estate of Jeanne F. Shelby, honors one faculty member in clinical research and one in basic or translational research. Gershenwald’s surgical oncology field focuses on the clinical management of cancer, while Bedford’s discipline investigates epigenetic regulation, the molecular systems that influence how genes are activated or silenced without changing the underlying DNA sequence. Such research can reveal why tumors behave differently and may identify vulnerabilities for future therapies.

The Shirley Stein Scientific Endowed Research Award went to Ethan Lin, M.D., assistant professor of Interventional Radiology, and Hongxia Sun, M.D., Ph.D., associate professor of Anatomic Pathology. The award provides $10,000 for preliminary data generation, a critical stage in the development of clinical research programs. Early data can help investigators test whether a hypothesis is biologically plausible, refine study methods and build the evidence needed to compete for larger federal or institutional grants. Interventional radiology uses image-guided procedures to diagnose or treat disease with minimally invasive techniques, while anatomic pathology examines tissues and cells to establish diagnoses and characterize the biological features of tumors.

Katy Rezvani, M.D., Ph.D., vice president and head of the Institute for Cell Therapy Discovery & Innovation, received the President’s Award for Leadership Excellence. She is also a professor of Stem Cell Transplantation and Cellular Therapy. The award combines the former John Mendelsohn Award for Faculty Leadership and the Charles A. LeMaistre Outstanding Achievement Award in Cancer. Her area of work is part of a rapidly developing branch of oncology in which immune cells are collected, engineered or otherwise prepared to recognize malignant cells. Cellular therapies require close coordination among laboratory scientists, manufacturing specialists, transplant teams and clinical investigators, making institutional leadership essential to moving discoveries from research settings into patient care.

Six faculty members were named Faculty Scholars, a program recognizing assistant and associate professors with exceptional potential in research, education, patient care or prevention. The honorees are Hussein Abbas, M.D., Ph.D., assistant professor of Leukemia; Scherezade Mama, Dr.P.H., associate professor of Health Disparities Research; Amy Moreno, M.D., assistant professor of Radiation Oncology; Van Morris, M.D., associate professor of Gastrointestinal Medical Oncology; Natalie Vokes, M.D., assistant professor of Thoracic Head and Neck Medical Oncology; and Tao Wang, Ph.D., associate professor of Bioinformatics and Computational Biology. Their fields illustrate how cancer medicine increasingly depends on interdisciplinary expertise, including population science, radiation physics, disease-specific treatment and data analysis.

Bioinformatics and computational biology are particularly important as cancer research generates vast quantities of genomic, imaging and clinical information. Computational approaches can help researchers compare tumor samples, identify patterns associated with treatment response and organize complex data into testable biological models. Health disparities research, meanwhile, examines how social, economic, geographic and structural factors influence exposure to risk, access to screening and the likelihood of receiving timely, high-quality care. By recognizing both areas alongside disease-focused specialties, the Faculty Scholar Program reflects a broader view of cancer control that includes biology, technology and the conditions in which patients live.

The Faculty Achievement Awards honored six additional faculty members for original contributions across basic science, prevention, clinical research, education, patient care and translational research. Betty Kim, M.D., Ph.D., professor of Neurosurgery, received the basic science research award. Sanjay Shete, Ph.D., professor of Biostatistics, was recognized for cancer prevention. Rodabe Amaria, M.D., professor of Melanoma Medical Oncology, received the clinical research award, while Phyu Aung, M.D., Ph.D., professor of Anatomic Pathology, was honored for education. Peter Balter, Ph.D., professor of Radiation Physics, received the patient care award, and Tina Cascone, M.D., Ph.D., associate professor of Thoracic Head and Neck Medical Oncology, was recognized for translational research.

The range of disciplines represented by the awards underscores the complex pathway from discovery to medical impact. Basic science can identify mechanisms that drive tumor growth; biostatistics can determine whether an observed result is reliable; prevention research can reduce risk before cancer develops; and clinical trials can establish whether a promising intervention benefits patients. Radiation physics contributes to the precision and safety of treatment planning, while pathology provides the diagnostic and molecular information needed to classify disease. Translational research connects these stages by testing how findings from laboratories, models and early studies can be adapted to real-world clinical practice.

The celebration also recognized faculty excellence in quality improvement and patient safety, research, community engagement, education and mentorship. These areas may receive less public attention than dramatic laboratory discoveries, but they are essential to dependable cancer care. Quality improvement uses systematic measurement to identify weaknesses in clinical processes and test changes that improve outcomes. Patient-safety programs seek to prevent avoidable harm by examining communication, medication use, procedures and institutional workflows. Community engagement and education can strengthen prevention and early detection, while mentorship helps sustain the next generation of investigators and clinicians. Through its awards and promotions, UT MD Anderson presented cancer progress as a collective enterprise in which scientific innovation, clinical expertise and institutional responsibility are inseparable.

Subject of Research: Cancer research, oncology, cancer prevention, cellular therapy, clinical care, medical education and patient safety.

Article Title: UT MD Anderson Honors Faculty Advancing Cancer Research, Care and Prevention

News Publication Date: August 20, 2026

Web References: UT MD Anderson Cancer Center; https://www.mdanderson.org/

References: University of Texas MD Anderson Cancer Center, Celebration of Faculty Excellence announcement.

Image Credits: UT MD Anderson

Keywords: cancer research, oncology, cancer prevention, faculty awards, UT MD Anderson, clinical research, translational research, cellular therapy, bioinformatics, patient care, health disparities, radiation oncology, cancer education

In 2023, breast cancer accounted for approximately 2.3 million new cases worldwide, accompanied by 764,000 deaths among women. This translates to a staggering loss of roughly 24 million healthy life years, a metric combining years lost due to premature mortality and years lived with disability. These figures emphasize the profound toll breast cancer exacts, not only on the individuals affected but also on communities and healthcare systems globally. Importantly, the analysis underscores that over a quarter of these healthy life years lost are attributable to six modifiable lifestyle risk factors, prominently including high red meat consumption, tobacco exposure, elevated blood glucose levels, and high body mass index (BMI). This identification of preventable contributors opens vital avenues for targeted public health interventions.

Projections paint a sobering future: by 2050, new breast cancer cases in women are expected to surge by 55%, escalating from 2.3 million in 2023 to over 3.5 million. Concurrently, the annual mortality rate is forecasted to increase by 44%, nearing 1.4 million deaths. These alarming trends disproportionately burden low- and lower-middle-income countries (LMICs), exacerbating existing health inequities. The persistent upward trajectory in breast cancer incidence in these regions is linked to demographic transitions and lifestyle changes intersecting with constrained healthcare infrastructure, including limited access to early diagnostic modalities, radiotherapy, chemotherapy, and expert pathology services.

Age-standardized incidence rates (ASIR) illustrate paradoxical patterns: high-income countries (HICs) maintain the highest incidence rates, with countries like Monaco, Andorra, and Germany exhibiting rates exceeding 100 cases per 100,000 women. In stark contrast, many LMICs report substantially lower ASIRs, sometimes below 13 per 100,000. However, since 1990, low-income countries (LICs) have experienced an exponential rise in ASIR by an average of 147%, compared to relatively stable rates in HICs. This disproportionate increment signals an urgent need for surveillance and tailored intervention frameworks in these rapidly evolving environments.

Equally concerning are mortality trends. Age-standardized mortality rates (ASMR) in HICs have declined by 30% since 1990, attributable to advances in early detection, screening programs, and therapeutic innovations. Conversely, mortality rates in LICs have nearly doubled within the same timeframe, reflecting systemic delays in diagnosis and inadequate treatment accessibility. Consequently, women in LMICs, although representing just 27% of global new cases, endure over 45% of global breast cancer-related morbidity and mortality, translating into nearly 11 million years of healthy life lost.

The analysis also highlights shifting age demographics in breast cancer incidence. While women aged 55 and older account for thrice as many new cases as their younger counterparts aged 20-54, recent decades have witnessed a 29% increase in incidence among younger women. This uptick in premenopausal breast cancer incidence may reflect evolving risk factor profiles and underscores the heterogeneity of breast cancer etiologies among different age groups. Understanding these patterns is vital for developing age-appropriate screening and prevention policies.

Risk factor analysis, central to the study, reveals that 28% of the breast cancer burden in 2023 is linked to six modifiable lifestyle factors, of which high red meat intake holds the most significant weighting, contributing to nearly 11% of healthy life years lost. Tobacco use, including exposure to secondhand smoke, constitutes 8%, followed by hyperglycemia (6%) and high BMI (4%). Notably, burdens linked to high alcohol consumption and physical inactivity each account for 2%. Encouragingly, declines in alcohol and tobacco-related breast cancer burdens were observed since 1990, reflecting effective public health campaigns, though no significant improvements were noted for other risk factors, reinforcing the need for intensified intervention efforts.

The study’s granular country-level examination identifies regions with the most pronounced changes. Equatorial Guinea, for instance, exhibits the largest increase in ASIR, rising by a staggering 354%, while the Lao People’s Democratic Republic shows the greatest surge in mortality rates, with ASMR increasing by more than 200%. Contrastingly, Denmark demonstrates the most substantial declines in both incidence and mortality, a testament to successful national cancer control strategies.

Healthcare system capacity emerges as a critical determinant of outcomes. The gap in access to quality care, particularly in LMICs, translates into later-stage diagnoses and limited availability of cutting-edge treatments. The shortage of essential healthcare infrastructure, such as radiotherapy units and pathology services, compounds these disparities. Furthermore, the high cost of standard treatments often renders them inaccessible to the most vulnerable populations, exacerbating inequities and undermining survival prospects.

Despite the progress, the study acknowledges significant limitations, chiefly the paucity of high-quality cancer registry data in many countries, especially those with limited resources. The absence of detailed data on cancer stage at diagnosis and molecular subtypes impedes nuanced survival analyses and tailored treatment approaches. Additionally, the impacts of recent global disruptions—such as the COVID-19 pandemic and geopolitical conflicts—remain unexplored, though likely influential on diagnosis delays and treatment interruptions.

To confront these challenges, the authors advocate for a multifaceted approach encompassing aggressive prevention efforts targeting modifiable risk factors, strengthening health systems capable of early detection and comprehensive treatment, and ensuring equitable access to affordable cancer services. The enhancement of cancer surveillance infrastructures is imperative for accurate burden assessment and to monitor intervention efficacy. Moreover, collaborative international efforts and political commitment are crucial to mobilize resources and implement sustainable breast cancer control measures.

This comprehensive global assessment illuminates a pivotal juncture in breast cancer control. It encapsulates a call to action emphasizing that, while lifestyle modifications could abate a significant fraction of the disease burden, millions will continue to require timely and effective treatment. The secretion of health equity—ensuring all women, irrespective of geography or socioeconomic status, receive optimal care—remains the cornerstone of future progress.

In conclusion, the study by the Global Burden of Disease Breast Cancer Collaborators elucidates the complex epidemiology of female breast cancer from 1990 to 2023, with projections extending to 2050. It underscores profound global disparities in incidence and mortality trends, driven largely by healthcare inequities and modifiable lifestyle factors. Addressing these gaps through targeted public health policies, systemic healthcare improvements, and expanded research investment is vital to mitigate the looming breast cancer burden and save millions of lives globally.

Subject of Research: Global epidemiology, burden, and risk factors of female breast cancer covering 204 countries from 1990 to 2023 with forecasts to 2050.

Article Title: The Global Shift and Escalation of Breast Cancer Burden: A Comprehensive Analysis of Incidence, Mortality, and Preventable Risk Factors

News Publication Date: 2024

Web References:

• Full article link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext
• Country-level data: https://cloud.ihme.washington.edu/s/iDnqW7jaPz7ENcB

The foundation of the TOP lies in its transdiagnostic framework, which means it targets a broad spectrum of symptoms and problems common across different cancer types and treatments. Traditional aftercare programs often focus on disease-specific issues or singular dimensions of recovery. In contrast, TOP integrates family doctor-led consultations with a carefully orchestrated suite of therapies including exercise, mind-body techniques, sleep hygiene education, personalized nutritional guidance, and optional psychological therapy. This multidisciplinary model reflects an understanding that cancer survivorship is multifaceted, requiring interventions that address physical, emotional, and lifestyle domains concurrently.

This before-and-after pilot study enrolled nineteen cancer survivors who participated in the 12-month interdisciplinary program in primary care. An equally composed group of sixteen survivors who declined participation were recruited as controls to gauge preliminary effectiveness. Attendance and attrition rates were carefully monitored to assess feasibility and acceptance, as these metrics are critical for evaluating real-world applicability. Participants underwent thorough assessments at baseline and after 12 months, employing validated instruments like the EORTC QOL-C30 to evaluate global health status, functional domains, and symptom burden, alongside measures for fatigue, psychological distress, happiness, and work ability.

One of the most striking findings emerged from analysis of quality-of-life measures. Despite starting with significantly lower baseline scores than controls, individuals in the intervention group exhibited substantial improvements in physical and social functioning by the end of the study period. This suggests that the multidomain approach not only arrests decline but may actively restore function and wellbeing in areas long compromised by cancer and its treatment. These gains in physical and social domains are particularly salient as they directly contribute to survivors’ capacity to engage in daily activities, maintain relationships, and reintegrate into work and community life.

Fatigue and anxiety, two of the most pervasive and debilitating symptoms reported by cancer survivors, also showed notable reductions in the intervention cohort. Fatigue in cancer survivors is widely acknowledged as a complex, multifactorial condition with physical, psychological, and behavioral components. By incorporating exercise, mind-body therapy, and sleep hygiene strategies, TOP addresses fatigue from multiple angles, presumably mitigating its impact more effectively than monodimensional treatments. Similarly, the decrease in anxiety levels highlights the potential psychological benefits of integrated aftercare programs rooted in primary care, where continuous and trusted relationships with family doctors can enhance therapeutic alliances and adherence.

The pilot study also provides valuable insights into the practical delivery of such programs. Dropout was low, with only three participants leaving due to personal or health-related challenges. Attendance rates were satisfactory, indicating strong acceptance among participants despite the program’s comprehensive and demanding nature. Satisfaction scores further corroborated the program’s feasibility, suggesting that patients appreciate a holistic approach addressing their unique constellation of needs rather than fragmented or disease-centric care. These operational successes underpin the rationale for scaling and rigorously testing TOP in larger, randomized controlled trials.

The transdiagnostic nature of TOP allows it to transcend traditional siloed care approaches. Cancer survivors frequently experience overlapping symptoms such as sleep disturbances, mood disorders, cognitive impairments, and physical deconditioning, which do not neatly fit into isolated treatment categories. By targeting these transdiagnostic issues, the program embodies precision medicine principles, tailoring interventions to individual symptom clusters irrespective of cancer types or stages. This inclusivity fosters equity in survivorship care and mitigates disparities stemming from disease-specific resource allocation.

From a mechanistic standpoint, the integration of lifestyle interventions in primary care post-cancer treatment has a solid theoretical basis. Exercise modulates inflammation, enhances cardiovascular fitness, and improves muscle strength, all important in counteracting cancer-related fatigue and functional decline. Mind-body therapies such as meditation and relaxation techniques reduce stress, which is implicated in both psychological symptoms and immune function. Sleep hygiene education addresses a critical yet underserved domain, as sleep disorders exacerbate both fatigue and mood disturbances. Nutritional counseling supports metabolic balance and overall vitality, completing the multifaceted approach necessary for holistic recovery.

Importantly, the study highlights the central role of family doctors as coordinators of survivorship care. Primary care physicians are well-positioned to deliver continuous, personalized, and accessible care, often having longstanding relationships with patients. Their leadership within interdisciplinary teams ensures consistent monitoring, early identification of emerging problems, and seamless referrals to specialized services when needed. This approach not only reduces care fragmentation but also addresses workforce sustainability challenges in oncology by leveraging primary care resources more effectively.

Despite promising outcomes, the authors caution that the small sample size and non-randomized design limit definitive conclusions regarding efficacy. Confounding variables inherent to pilot studies can influence observed effects, necessitating careful interpretation. Nonetheless, these initial results provide compelling pilot data to justify larger scale investigations. Randomized controlled trials comparing TOP with standard care are essential to establish its true impact on quality of life, symptom management, and possibly survival outcomes.

This study’s implications extend beyond oncology to survivorship paradigms in chronic diseases more broadly. The transdiagnostic, multidomain model could inform aftercare for a spectrum of conditions characterized by complex symptom burdens and psychosocial sequelae. Integrating lifestyle medicine principles into primary care-led programs promises a more sustainable and patient-centered approach to long-term health management, emphasizing prevention, rehabilitation, and quality of life enhancement simultaneously.

In conclusion, the Transdiagnostic Oncology Program represents a visionary step towards reimagining survivorship care as a holistic, interdisciplinary endeavor embedded within primary care. Its multidomain lifestyle interventions address the intricate tapestry of physical, psychological, and social challenges facing cancer survivors, marking a crucial advancement in post-treatment medicine. While further research is required to substantiate these preliminary findings, TOP lays an important foundation for improving quality of life where it matters most: in the communities where survivors live, work, and thrive.

Subject of Research: Quality of life improvement in cancer survivors through a primary care-led, multidomain lifestyle intervention program.

Article Title: The Transdiagnostic Oncology Program (TOP): a multidomain lifestyle intervention to improve the quality of life of cancer survivors – a before-and-after pilot study in primary care.

Article References:
Booij, S.H., Pieper, A., Wester, C.D. et al. The Transdiagnostic Oncology Program (TOP): a multidomain lifestyle intervention to improve the quality of life of cancer survivors – a before-and-after pilot study in primary care. BMC Cancer 25, 1745 (2025). https://doi.org/10.1186/s12885-025-15063-2

Image Credits: Scienmag.com

DOI: 10 November 2025

Keywords: Cancer survivorship, quality of life, transdiagnostic intervention, multidomain lifestyle program, primary care, fatigue management, psychological symptoms, exercise therapy, mind-body therapy, sleep hygiene, nutrition, interdisciplinary care, feasibility, pilot study